- Summits
- Sponsorship
- Media Opportunities
- News
- About
Medtronic has completed its acquisition of Scientia Vascular, a privately held medical device company based in Salt Lake City, in a deal valued at $550 million, subject to customary adjustments and potential future milestone payments.
The acquisition brings Scientia’s portfolio of guidewires and catheters into Medtronic’s neurovascular business, expanding the company’s ability to support physicians treating complex neurovascular conditions such as stroke and aneurysms. By integrating Scientia’s access technologies with its existing therapeutic offerings, Medtronic aims to provide a more comprehensive platform across the neurovascular procedural workflow.
Scientia has built its reputation on developing access products designed to help physicians navigate the highly complex anatomy of the brain’s blood vessels. These technologies are intended to improve access to treatment sites, reduce procedural challenges, and support more efficient interventions.
Rick Randall, CEO of Scientia, described the acquisition as a natural next step for the company.
“Since its founding, Scientia has been driven by a commitment to improving patients’ lives and supporting the physicians who care for them,” said Randall. “Joining Medtronic is an exciting next step for our team, as their Mission closely aligns with the values that have guided Scientia from the beginning. With Medtronic’s global scale, we look forward to bringing this technology to more physicians and reaching more patients around the world.”
The transaction comes at a time when the need for effective neurovascular interventions continues to grow. Stroke remains the third leading cause of death and the leading cause of disability worldwide. In acute stroke treatment, rapid restoration of blood flow is critical, as the brain loses millions of cells every second during an ischemic event.
One of the challenges physicians face in neurovascular procedures is the complexity of cerebral vasculature. The intricate and tortuous pathways of blood vessels in the brain can make it difficult to reach the site of an occlusion or aneurysm, potentially delaying treatment and affecting procedural outcomes.
Scientia’s access platform was developed specifically to address these challenges. Its technologies are designed to improve navigability through complex anatomy, helping physicians reach treatment sites more efficiently and with greater confidence.
According to Medtronic, the addition of these technologies will strengthen its ability to deliver integrated solutions that support both access and therapy delivery.
“The addition of Scientia’s access technologies strengthens our ability to simplify complex neurovascular procedures and support physicians with more seamless solutions,” said Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business, part of the Neuroscience Portfolio at Medtronic. “By bringing together highly complementary technologies, we are building a more integrated platform that will help advance the future of neurovascular care and enable physicians to treat more patients with greater efficiency and confidence.”
The acquisition reflects Medtronic’s continued strategy of investing in technologies that complement its existing portfolio and strengthen its position in key growth areas. By combining Scientia’s access products with its established neurovascular therapies, the company aims to enhance procedural workflows for physicians and support better patient outcomes.
Founded in Salt Lake City, Scientia has developed a range of access technologies under the leadership of founder and Chief Technology Officer John Lippert. The company’s guidewires and catheter systems are designed to integrate with existing neurovascular treatment platforms, making them a strategic addition to Medtronic’s portfolio.
As neurovascular procedures continue to evolve, the combination of access and therapeutic technologies is expected to play an increasingly important role in helping physicians treat complex cerebrovascular conditions more effectively. Through this acquisition, Medtronic is positioning itself to offer a broader suite of solutions designed to improve procedural efficiency and expand access to advanced neurovascular care worldwide.
As MedTech companies continue to expand their portfolios through strategic acquisitions, partnerships, and technological innovation, industry leaders from across the healthcare ecosystem will gather at MedTech World Asia 2026, taking place 26–28 August 2026 at the Hong Kong Convention and Exhibition Centre. The event will bring together innovators, investors, manufacturers, healthcare providers, and decision-makers to explore opportunities across the Asia-Pacific market, share insights on industry trends, and build connections that support growth and collaboration in MedTech. Learn more and secure your place at MedTech World Asia 2026.
